Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Claritrebin-containing reinduction regimens in newly treated pediatric AML (non-M3)
ChiCTR2200057563Phase 4Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of cladribine in acute myeloid leukemia (AML) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Complete response rate after reinduction therapy (CR+CRi). Started Mar 2022; status: recruiting.
02
Drugs
cladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200057563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057563.